Your browser doesn't support javascript.
loading
Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge.
van der Lubbe, Joan E M; Huizingh, Jeroen; Verspuij, Johan W A; Tettero, Lisanne; Schmit-Tillemans, Sonja P R; Mooij, Petra; Mortier, Daniella; Koopman, Gerrit; Bogers, Willy M J M; Dekking, Liesbeth; Meijberg, Wim; Kwaks, Ted; Brandenburg, Boerries; Tolboom, Jeroen T B M; Schuitemaker, Hanneke; Roozendaal, Ramon; Kuipers, Harmjan; Zahn, Roland C.
Affiliation
  • van der Lubbe JEM; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Huizingh J; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Verspuij JWA; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Tettero L; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Schmit-Tillemans SPR; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Mooij P; 2Department of Virology, Biomedical Primate Research Centre, P.O. Box 3306, 2280 GH Rijswijk, The Netherlands.
  • Mortier D; 2Department of Virology, Biomedical Primate Research Centre, P.O. Box 3306, 2280 GH Rijswijk, The Netherlands.
  • Koopman G; 2Department of Virology, Biomedical Primate Research Centre, P.O. Box 3306, 2280 GH Rijswijk, The Netherlands.
  • Bogers WMJM; 2Department of Virology, Biomedical Primate Research Centre, P.O. Box 3306, 2280 GH Rijswijk, The Netherlands.
  • Dekking L; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Meijberg W; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Kwaks T; 3Present Address: Innovation Exchange Amsterdam, IXA Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
  • Brandenburg B; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Tolboom JTBM; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Schuitemaker H; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Roozendaal R; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Kuipers H; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
  • Zahn RC; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
NPJ Vaccines ; 3: 25, 2018.
Article in En | MEDLINE | ID: mdl-29977611
Seasonal vaccines are currently the most effective countermeasure against influenza. However, seasonal vaccines are only effective against strains closely related to the influenza strains contained in the vaccine. Recently a new hemagglutinin (HA) stem-based antigen, the so-called "mini-HA", has been shown to induce a cross-protective immune response in influenza-naive mice and non-human primates (NHP). However, prior exposure to influenza can have a profound effect on the immune response to subsequent influenza infection and the protective efficacy of vaccination. Here we show that mini-HA, compared to a trivalent influenza vaccine (TIV), elicits a broadened influenza-specific humoral immune response in NHP previously exposed to influenza. Serum transfer experiments showed that antibodies induced by both mini-HA and seasonal vaccine protected mice against lethal challenge with a H1N1 influenza strain heterologous to the H1 HA included in the TIV. However, antibodies elicited by mini-HA showed an additional benefit of protecting mice against lethal heterosubtypic H5N1 influenza challenge, associated with H5 HA-specific functional antibodies.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Vaccines Year: 2018 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Vaccines Year: 2018 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom